List of Biotech, Pharmaceutical & Life Sciences companies in New Jersey - 225

3D Biotek, LLC is a high tech biomedical engineering company located in the state of New Jersey, USA. Using its Precision 3D Micro-fabrication Technology and Advanced Bio-manufacturing Technology, 3D Biotek is a leader and the industry's only dedicated driving force in the research and development of novel 3-dimensional cell culture devices for stem cell/tissue engineering, drug discovery and broad cell biology applications.

4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer's disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.

An early stage start-up with three products in Pre-IND phase and several complex generics in the pipeline.

AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life. AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use. AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises. AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.

Accu Reference Medical Lab is a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. We are certified under the federal government’s Clinical Laboratory Improvement Amendments (CLIA) and operate in compliance with all governmental regulations. We use the latest diagnostic technology. As new medical tests become available, we update our list of services. Our laboratory technicians are well trained and have many years of experience, providing the most accurate and precise testing results. We also continuously strive to improve the quality of our testing, data handling and reporting through integrating robust technique and technological advancements. Accu Reference Medical Lab is an equal opportunity employer.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise focusing on oral dosage forms for the Pharmaceutical industry. Adare's specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactures more than 45 products sold by customers worldwide.

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

AeroFarmsis an indoor vertical farming company. They usea patented aeroponic growing system to grow produce.

Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.

Alfa Wassermann Diagnostic Technologies is a provider of medical diagnostic instrumentation and reagents to the physician office, veterinary lab, and biopharmaceutical markets.

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Althera is focused on development and supply of innovative patient focused medicines. Althera’s medicines are approved and available to patients in more than 35 countries worldwide. ​Founded in 2010, we are leaders in development of innovative combination medicines in therapeutic areas of Cardiology and Diabetes, and work closely with our B2B partners in making these products available to patients in geographies across the world including all major markets in Europe and Emerging Markets including Asia, Latin America and Africa. ​Our strong R&D capabilities and network of manufacturing sites enable innovative and cost effective supply of medications to improve patient health.

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people's lives better by making high quality medicines more accessible around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.

American CryoStem Corporation (CRYO) is a clinical-stage biotechnology company, developing and delivering autologous (own self) regenerative therapies to treat diseases and conditions with significant unmet medical needs. We are prioritizing research targets and biological drug candidates where the disease biology is understood, and where our suite of technologies has the potential to make a difference. We are currently focused on mitigating the deleterious effects of post-concussion syndrome: https://clinicaltrials.gov/ct2/show/NCT04744051 and Long COVID/ PASC: Post Acute Sequelae of SARS-CoV-2 https://clinicaltrials.gov/ct2/show/NCT05669261 Translating Technology into Therapeutic Treatments™ Our core proprietary "end-to-end" patented technology platform consists of the “Collection-Processing-Cryobanking and Delivery to Point-of-Care” of Adipose Tissue (AT) and Adipose-Derived Mesenchymal Stem Cells (MSCs). Our Platform is configured to produce large quantities of autologous mesenchymal stem cells for treatments as needed, "on-demand". Through a single tissue collection, an autologous master cell sample is manufactured and cryopreserved for a lifetime of personalized treatments. Naturally, pure and simple.™

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we're dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix's Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

Apicore LLC, a wholly owned subsidiary of RK Pharma Inc (www.rkpharmainc.com), is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are both equipped with state-of-the-art analytical and research capabilities. While our worldwide network of locations seamlessly integrate with each other, each unit also independently houses a full suite of R&D, QA, QC, and Manufacturing Services. This facilitates a continuous real-time exchange of information, ideas, and data while eliminating redundancies and waste. Our managing partners have over 60 years worth of experience in the pharmaceutical world, encompassing small, mid and large pharmaceutical companies throughout the world. Our Mission is to develop, manufacture, and deliver API’s, with superior quality and regulatory support, at competitive costs.

API Pharmatech is focused on delivering Quality therapeutic products, satisfying Regulatory and Statutory necessities thereby, ensuring safety and purity to its products. We indulged in developing and manufacturing generic and innovative APIs and FDFs. Well capable of resources and expertise to pull out an API from development to commercial scale manufacturing, fulfilling all the required statutory regulations and inspections and involving in the development, manufacturing and marketing of the drug. API Pharmatech constantly updates its knowledge and identifies niche and complex APIs and FDFs which are technologically challenged.

Apprentice provides an all-in-one, cloud-native platform (Tempo Manufacturing Cloud) that is purpose-built for regulated industries, and covers a wide range of manufacturing use cases across multiple industry verticals. Within life sciences, Tempo accelerates the end-to-end drug product lifecycle by connecting together distributed teams and sites, helping them execute better on the shop floor, and optimizing their operations through enterprise-wide visibility. Apprentice is trusted by global manufacturing leaders across various regulated industries. Tempo users belong to organizations responsible for contract manufacturing, cell & gene therapy, CRISPR technology, biopharma, biotechnology and adjacent industries.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.

Arbela Labs is a New Jersey-based company focused on increasing the scale and reducing the costs of biomanufacturing using its methanol-fed Pichia platform.

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia Pharmaceuticals is your ideal partner for: · Early stage IND-enabling formulations for toxicology and pharmacokinetic (PK) studies · Rapid development through Phase I CTM materials for oral and parenteral dosage forms · Fast discovery formulation support · Formulation development and CTM manufacturing for specialty pharmaceuticals Ascendia Pharmaceuticals also provides special development programs: · Formulations for poorly soluble and low bioavailability drugs · First-in-man injectable formulations · Nano-emulsion and nano-particle formulations · Peptide formulations · Sustained release by parenteral or oral routes · Development of 505(b)(2) products · Development of complex generics · High potency and DEA controlled drug substances · Ocular formulation development · Animal health formulations

ASCEND Therapeutics US, LLC is a specialty pharmaceutical company concentrating on women’s health. With a century of innovation originating with our parent company, Besins Healthcare, ASCEND Therapeutics continues to attain high standards in commercial and product development. ASCEND THERAPEUTICS U.S., LLC is a pharmaceuticals company based out of 15 Mt Kemble Ave Morristown, NJ 07960

Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology-based company focusing on the development and commercialization of Branded Specialty Products and Technology Platform-based Niche Generics. Aucta is a pharmaceutical company creating enhanced products from proven molecules using the 505(b)(2) regulatory pathway. Through innovation, Aucta is creating new therapeutics, including new dosage forms, new dosing regimens, and new indications. Aucta has a clear therapeutic focus in CNS disorders, Ophthalmic, and Inhalation Therapy. We are committed to being patient-centric by continuously bringing improved forms of proven molecules into the marketplace. Aucta has operation in both New Jersey, U.S. and Shanghai, China. Our mission: Enhanced products from proven molecules!

AustarPharma is a pharmaceutical company that specializes in drug delivery technologies.

Avalon GloboCare Corp. is an intelligent biotech developer and healthcare service provider. The Company engages in the management of stem cell banks and specialty clinical laboratories. It is developing of exosome technology to improve the diagnosis and management of diseases. The Company operates through two platforms, Avalon Cell and Avalon Rehab. Its technology and service ecosystem covers the areas of regenerative medicine, cell-based immunotherapy, exosome technology, as well as rehabilitation medicine. The Company also focused on diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and the discovery of disease-specific exosomes to provide the disease origin insight necessary to enable.

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we’re dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix’s Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.

Avotres Inc. is a private biotechnology company developing breakthrough therapeutic solutions for incurable immunologically mediated disorders. Targeting these therapeutic areas with significant unmet medical needs, we apply innovative science to unveil potentially paradigm shifting immunological pathways in the hope to transform the treatment for millions of patients. We consider it our mission to tackle these diseases from their root cause(s) and aim to reach the goal of relieving patients from the disease burden.

BASF Corporation is the largest affiliate of BASF SE and the second largest producer and marketer of chemicals and related products in North America. BASF creates chemistry for a sustainable future. They combine economic success with environmental protection and social responsibility.BASF Corporation operates more than 100 production and research and development sites throughout North America and operates Verbund sites in Geismar, Louisiana and Freeport, Texas. At Verbund sites, production plants, energy and material flows, logistics, and site infrastructure are all integrated.

An innovation driven start up company catering to the unmet needs of the biomaterial community and medical device industry. With our state of the art research and development facilities in theUS and India, combined with our platform technologies derived from a family of novel and proprietary biodegradable polymeric biomaterials, we work with and for our customers to translate their demands into high quality products for a wide range of medical device and therapeutic applications in a cost effective manner. Our expertise lies in the area of absorbable polyurethanes, absorbable polymers derived from functionalized natural products, drug molecules and amino acids, adhesion prevention barriers, absorbable drug eluting stent coatings, tissue adhesive and sealant, medical device coatings, drug delivery, drug device combination, absorbable implantable devices and tissue engineering.

Commercializing Ground Breaking Discoveries in Inflammation and Infection BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.

BioCentriq is a premier contract development and manufacturing organization (CDMO) dedicated to advancing cell therapy. Since 2019, the company has specialized in GMP autologous and allogeneic cell therapies, offering end-to-end clinical-to-commercial capable services tailored to clients’ unique needs. Operating from two state-of-the-art U.S.-based facilities, BioCentriq provides a comprehensive range of services, including technology transfer and new technology evaluations, process and analytical development, cGMP manufacturing, quality control lot release, and stability studies. The company’s expertise spans diverse cell therapy modalities, such as T-cell (CAR-T, TCR), NK-cell, iPSC, and MSC-based products. With its proprietary LEAP™ manufacturing platform, BioCentriq accelerates service timelines while offering standardized and customizable solutions, including traditional fee-for-service, hybrid and person-in-plant operations, dedicated cleanroom capacity, and flexible service and contract arrangements. In addition to its technical capabilities, BioCentriq operates the Cell and Gene Therapy Experiential Learning Center, a training facility which provides hands-on and virtual instruction under the guidance of industry-experienced instructors and subject matter experts. The program has trained hundreds of participants, hosted major pharmaceutical companies, and integrates next-generation technologies and concepts into its curriculum including: Industry 4.0 and Lean principles, predictive analytics, augmented reality, and electronic batch record systems. Backed by GC Corporation, a South Korea-based leader in the healthcare, pharmaceutical and biotechnology industry, BioCentriq combines global expertise with a flexible working relationship, set to empower clients to develop and deliver cutting-edge, personalized therapies with unmatched precision and efficiency.

BioInvenu is dedicated to developing assay products and services by utilizing a novel cell-based protein-protein interaction assay technology, LinkLight™ technology. The LinkLight™ technology was originally invented in Sanofi-Aventis. The technology utilizes protein-protein interactions as the functional signal readout. Protein-protein interaction is an essential cellular process regulating signal transductions in a living cell. Specific protein-protein interactions define signal transduction pathways. Ligand-induced transient protein-protein interactions are therefore of particular interest as the intervention points for drug discovery. The LinkLight™ technology has been applied to G-protein coupled receptors (GPCR), nuclear hormone receptors (NHR), and receptor tyrosine kinases (RTK) by utilizing receptor and its signal adaptor interaction as the functional signal readout. Biologically relevant compounds that modulate protein-protein interactions can be identified with this highly sensitive, specific, and robust assay method. The technology has the potential for applying a broad range of drug targets that are difficult to tackle by existing methods. In addition to finding molecules that modulate protein-protein interaction signal cascades, the technology can be applied to protein-protein interaction drug targets by identifying molecules directly blocking protein-protein interactions.

Bionex’s mission is to realize the applications of bio-pharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development, cGMP clinical supply manufacturing to full-scale commercialization, for bio-pharmaceutical products. Second, Bionex develops and out-licenses its own proprietary formulations, drug delivery technologies, and products related to medical, health food, and skin-care applications. Our expertise is focused on transdermal and transmucosal drug systems. We adopt a science-based, and yet pragmatic and out-of-box approach which often leads to fruitful outcomes, in time- and cost-effective manner. Bionex capabilities are its expertise in formulation science and analytical chemistry, full range of formulation/processing, analytical, and testing capabilities in cGMP facility, and well-connected network of industrial, academic and business consultants and advisors. Many of our in-house innovation R&D projects are funded by National Institute of Health (NIH), National Science Foundation (NSF), state grants and non-for-profit organizations.

BioPharm International® covers all aspects of biopharmaceutical development, analysis, processing, and packaging, as well as business strategies and regulatory issues. The print and digital editorial coverage provides technical and business insight and analysis for all biologic-based therapies including monoclonal antibodies, vaccines, biosimilars, protein therapeutics, cell therapies, gene therapies, antibody-drug conjugates, and other emerging therapies.

CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitations. Our underlying and core novel technologies enable the development of allogenic treatments for a spectrum of human diseases, including solid tumors and hard-to-treat cancers. Our therapeutic agents are expected to show superior safety profiles, including a low risk for cytokine release syndrome. Importantly, our technology will greatly reduce the complexities of manufacturing that are associated with whole-cell therapies, thereby minimizing the time, cost, and variability risk to facilitate greater access for patients in need.

At Castor, we believe in the power of clinical research and the power of technology. And we know that together, these forces can help extend human healthspan. To achieve this reality, we must make patient-centered clinical trials a possibility for everyone, anywhere in the world. That's why we are using technology to capture the world's research data and optimize each activity of a clinical trial. From recruitment to monitoring, our modular clinical trial platform makes it easier to design and deploy trials, enroll and engage patients, collect data and analyze results. Each module can be used individually or in unison with others, providing the ability to customize each solution to fit your needs, and grow at your own pace. That's delightful for patients, effortless for study teams, risk-free for sponsors.

Catherych Incorporated is an ingredient supplier to the natural products and nutraceuticals industry.

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Instagram, YouTube, and Facebook.

CELLSEARCH develops circulating tumor cell tests for determining the prognosis of patients with metastatic breast, prostate and colorectal cancers.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes and the Company intends to explore these and other compounds for the treatment of additional pain indications.

API Services

Chemo Mouthpiece, LLC is an oncology supportive care company. We are proud to introduce our new device, the Chemo Mouthpiece™. The Chemo Mouthpiece™, is a new 510(k) cleared device for marketing in the US. This device is intended to be used to cool the oral mucosa to reduce the incidence and severity of chemotherapy induced oral mucositis, a painful and debilitating side effect. Historically, oral cryotherapy was used for short half-life drugs only, the Chemo Mouthpiece™ shifts that paradigm by studying its efficacy in multiple long half-life drugs, giving you and your patients a better choice!! The Chemo Mouthpiece™ device was developed based on the personal experience of inventor, founder and CEO David Yoskowitz, who when diagnosed with Hodgkin’s Lymphoma experienced oral mucositis firsthand. His treatment options included ice chips to mitigate and minimize the pain. Yet this caused nausea, was difficult to maintain in his mouth, and did not effectively cool the entire oral cavity which led him to search for a better option. An engineer by trade, he made it his mission to find a better way for cancer patients to cope with oral mucositis during treatment. He created a simple, effective, easy-to-use device to be used during chemotherapy treatments at home or in a hospital. The Chemo Mouthpiece™ efficiently cools the entire oral cavity. Patients can freeze the device at home and take it with them to be used during treatment, creating a simple solution for an unmet patient need.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Claris Bio works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision-making. The company is focused on developing topical formulation technology designed to treat orphan ophthalmic disorders, such as neurotrophic keratitis, and cure corneal diseases.

Collagen Matrix is a biotechnology company that specializes in developing medical devices and products for regenerative medicine using collagen as a key component.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

Couragene believes that delivery of gene and biologic therapies should be safer and more efficient. Delivery of genome modification therapies to brain is further complicated by the physiological barriers. Couragene's STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders.

Established in 2010, Crystal Pharmatech is a specialized CRO/CDMO, excelling in crystal form and formulation services. Our exceptional track record includes supporting 1,000 clients and collaborating on over 2,000 compounds, showcasing our expertise in solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. With a global presence encompassing three strategically located R&D centers in New Jersey (USA), Toronto (Canada), and Suzhou (China), we are powered by a skilled team of around 250 professionals. As a leader in both conventional and enabling formulation technologies, including amorphous solid dispersion, we take pride in our cGMP facilities, strictly adhering to the rigorous standards set by the FDA, EMA, and NMPA. Our integrated service encompasses the entire new drug development journey, from developability assessment and solid form screening to pre-formulation, formulation development, and CTM and commercial manufacturing. Introducing our pioneering Mol2Med program, designed to expedite small molecule lead compounds or preclinical candidates into Phase I and beyond, with unparalleled efficiency and precision. This 3-step First-Time-Right approach begins at the lead optimization/PCC stage: Step 1: Developability Assessment to guide API form selection and formulation design. Step 2: Solid form screening/selection and Preformulation. Step 3: Formulation development and CTM manufacturing, including packaging, labeling, and shipping to the clinical site. This innovative approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, our First-Time-Right approach sets the foundation for optimized drug development and success beyond.

Validation Consulting

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

DermaRite manufactures cost-effective skin care, wound care, and nutritional supplements for healthcare facilities, including hospitals, nursing homes, hospice, and home care. Founded in 1995, DermaRite's state of the art manufacturing and warehousing facility is in North Bergen, New Jersey. With a distribution and sales network throughout the United States, facilities can be assured of fast, reliable service and personalized attention. DermaRite customers also receive access to a wide range of clinical and educational tools, making us one of the best values in the industry. DermaRite is an FDA and OSHA approved manufacturer.

DiamiR developsand diagnostictechnology based on analysis of brain-enriched microRNA biomarkers in blood plasma.

DRG International, Inc. is a leading specialty medical diagnostics and equipment manufacturer, and distributor with operations in more than 110 countries. As a global innovator of high-quality medical diagnostics and equipment, DRG International, Inc.'s mission is to provide the medical and research community with cutting edge, effective tools to build a healthier future. DRG® offers various laboratory immunodiagnostic products and equipment. In addition, DRG®, in cooperation with major U.S. and foreign suppliers, is a leading distributor for cardiac, electrophysiology, and angiology equipment and supplies in certain markets. DRG® provides a complete range of services including delivery, customs clearance, installation, on-site training and technical support as well as after-warranty service.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

EDDA Technology, Inc. is an innovative leader in the rapidly growing field of imaging-guided cancer treatment. By adopting a fully quantitative, real-time interactive approach to imaging analysis, simulation and guidance, our next generation computer-assisted radiology and surgery solutions go well beyond advanced 3D image visualization. The award-winning IQQA® platform supports a patient-specific, disease-targeted, and multi-disciplinary approach to cancer treatment. With exceptional ease-of-use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up. The IQQA® platform provides targeted solutions to assist physicians in advanced clinical applications including: fast 3D quantitative analysis and visualization, highly automated volumetric organ/lesion segmentation & quantification, pre– & post–operative assessment, treatment planning & simulation, procedural guidance and monitoring, and Computer-Aided Detection (CAD).

In 2005, we were founded on a unified belief that neuromodulation could be used in novel ways to help patients break free from treatments they aren’t happy with. Because different modalities of neuromodulation had previously proven to be effective and safe, we recognized an opportunity to be the leader in this new frontier of medicine and took it head on. Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop safe and clinically backed treatments. Bringing new treatments to market will help improve patients'​ treatment options and lives.

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. We develop and assess therapeutics based upon their ability to make a meaningful impact for patients and their treatment experiences. We invest in proven and promising therapeutics at various stages of development and advance them through clinical and regulatory processes with the goal of commercializing improved treatment options for patients and the healthcare providers who treat them.

Elite Pharmaceuticals is a pharmaceutical company that specializes in drug manufacturing and healthcare solutions.

At embecta (formerly part of BD), we are singularly focused on improving the lives of people living with diabetes. With a 100-year legacy of developing and providing solutions to the diabetes community, today, we are a global medical technology company and leader in insulin delivery devices. More than 30 million people in over 100 countries rely on our pen needle and syringe products every day.  BD is the manufacturer of the advertised products.   Privacy Policy: https://www.embecta.com/en-us/about/policies/privacy-policy-statement 

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb'24 data.

Endomedix is a development stage, Medical Device venture, a C corp. The Company has developed a tunable polysaccharide platform that can produce a family of new biomaterials. The first spinoff of this platform is PlexiClot™ Absorbable Hemostat to control bleeding in brain & spinal surgeries, a $1.9B market. PlexiClot introduces the first fundamental innovation in bleeding control in these procedures since the current standard of care was introduced in 1945. The innovation is based on new mechanisms of action that will likely obsolete the current methods of relying on the biochemical action of thrombin and manual pressure to produce coagulation. PlexiClot will eliminate one cause of reoperations caused by current devices as documented in dozens of clinical publications. In addition to reducing the incidence of complications, PlexiClot is poised to save hospitals hundreds of millions of dollars in unreimbursed costs due to reoperation, lengthy hospital stays and early readmission to hospitals. PlexiClot's performance has been confirmed in 3 large animal trials, and Endomedix is currently planning to scale up production. PlexiClot's composition of matter, method of manufacture and mechanisms of action are protected by 8 issued patents, the most important of which expire in 2038. The Endomedix team is led by Richard Russo, a medical device vet with experience in prior start-ups with exits, and he is the lead cash investor. He has a history of success with new products, clinical & regulatory, and international. R&D is led by Piyush Modak, who leverages a small internal team through a constellation of renown subject matter experts. 18 neurosurgeons & physicians are investors. PlexiClot will be the 1st device approved by FDA specifically for brain surgery. This sector is marked by a high level of M&A activity, much of which occurs prior to final FDA approval. The program has drawn interest & support from surgeons and physicians, 18 of whom are investors.

Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company's initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho's assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company's pipeline.

Enzon is a New Jersey-based biopharmaceutical company that develops and commercializes medicines for the treatment of cancer.

Powering relentless science by developing and commercializing first-in-class treatments to address debilitating and potentially fatal diseases, including COVID-19 and other infectious diseases; autoimmune diseases including rheumatoid arthritis; cachexia associated with AIDS or cancer; and topical non-invasive treatments for sight-robbing retinal diseases.

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

Ethos Biosciences designs, develops, and manufactures diagnostics that are accurate, repeatable, and easy to use. Ethos Biosciences was formed as a subsidiary of Ott Scientific in 2018 to drive healthcare innovation by providing diagnostic tools for scientists and practitioners. In November 2018, Ethos Biosciences acquired the Exocell diagnostic operation in Philadelphia from Glycadia Pharmaceuticals. Exocell was founded in 1988 by Dr. Margo Cohen, MD/PhD to explore diagnostic and therapeutic solutions for diabetes. Exocell quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. The Exocell brand continues to service the top research, academic, and industrial institutions in the world. Ott Scientific is a family owned and operated group of specialty chemical manufacturing companies with expertise in monomers, polymers, microspheres, and reagents for the pharmaceutical, medical device, and diagnostic industries.

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.

Discover how Excelra, a leader in biopharma data and analytics, uniquely blends scientific understanding with technological expertise. This dual mastery empowers innovative drug discovery and development, transforming research data into actionable insights for groundbreaking discovery. 𝗘𝗺𝗽𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 Excelra's interdisciplinary approach combines life science expertise with cutting-edge technology. This leads to confident, data-centric decisions, simplifying your data-driven drug discovery journey and accelerating your research. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 At Excelra, collaboration is key. By co-creating solutions, we amplify your team's capabilities, blending scientific insight and technological acumen for more valuable discoveries and greater project control. 𝗙𝗿𝗼𝗺 𝗖𝗵𝗮𝗼𝘀 𝘁𝗼 𝗖𝗹𝗮𝗿𝗶𝘁𝘆: 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗗𝗮𝘁𝗮 We navigate the complexities of drug discovery, enhancing your success by structuring chaotic data into actionable insights, leveraging our scientific and technological prowess. 𝗖𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗚𝗼𝗮𝗹𝘀 Your goals of faster drug development and better patient outcomes are central to our mission. Committed to delivering insights and tangible progress, we ensure each data point contributes to your innovation journey, helping you 'Excelrate' towards success. 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 Join us in redefining drug development. Our services span across the life science value chain, from molecule to market. At Excelra, each data point is a step towards a healthier future. Discover how partnering with us can 'Excelrate' your healthcare innovations.

Are you ready for a better CDMO experience? You've found it. At Experic, we specialize in the development, clinical and commercial manufacturing, and global logistics services that help our biopharmaceutical customers succeed. Our 45,500-square-foot, state-of-the-art facility located in New Jersey is designed for advanced powder filling and low-dose dry powder inhalation products but is built to accommodate a variety of drug delivery formats, including liquids and highly potent products. From initial product concepts to manufacturing, packaging, and patients, our team of seasoned experts and project managers seamlessly blend cutting-edge capabilities and customized solutions tailored to your needs. Our end-to-end services include: • Formulation and process development • Spray drying expertise • Powder blending and filling • Risk-mitigation mindset • Clinical and commercial manufacturing • Encapsulation/over-encapsulation • Primary and secondary packaging • Robust quality culture • Full suite of analytical services • Global clinical trial logistics from our US & EU depots • Expansion space available for custom suites • Experic experts on-call to provide you with peace of mind Experience a new approach to product lifecycle support and partner with us today!

Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United States, China and other countries around the world.

Founded in 1986, General Technical Services L.L.C. (GTS) provides on-site and off-site Scientific, Engineering, Technical and Management support to US Government agencies, universities, and industry partners. GTS is a certified, Women Owned Small Business (WOSB) located in Wall Township, New Jersey. The majority of GTS’ Scientific and Technical staff have advanced degrees in science, engineering and management. Some of our leadership have had distinguished Government careers and all have over 30 years’ experience in execution and management of Government programs. The GTS team appreciates the importance and complexity of federal acquisitions, R&D activities and is well versed in program management and contract procedures. The GTS team has technical competence in scientific and engineering disciplines such as advanced RF technologies and sensors, advanced Electro-Optical technologies and sensors, electronic materials and devices, and, all aspects of tactical power and energy. We also provide Program Management and, when needed, administrative support. Primary clients are the US DoD Service RDT&E Centers and Laboratories as well as Federal Agencies and National Laboratories. For more information please contract Mr. Kurt Kovach, Executive VP for Strategy and Business Development at kurt.kovach@gtsllc.com.

Genesis Drug Discovery and Development (GD3), a member of Genesis Global Group, is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, ​and microbiome.

GENEWIZ from Azenta Life Sciences Company, is a leading global genomics service provider serving thousands of researchers in institutions worldwide. GENEWIZ offers a suite of solutions including DNA synthesis, sanger sequencing and next generation sequencing to accelerate antibody discovery and development research. Other services also include bioinformatics, GLP regulatory, and clinical services. From the company’s founding, GENEWIZ has maintained an unwavering commitment to providing customers with the best combination of quality, service, and value. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. At GENEWIZ, it is our mission to contribute to the advancement of life sciences and technologies. Together with our clients, we can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Our goal is to be the best in the world and the best for the world. Headquartered in Leipzig, Germany and South Plainfield, NJ, GENEWIZ has additional locations in Takeley, United Kingdom; Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; Seattle, WA, Beijing, China; Suzhou, China; and Tokyo, Japan.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

At Glucotrack, we are pioneers in diabetes technology, dedicated to transforming the way diabetes is managed. Our mission is to develop innovative, long-term solutions that prioritize accuracy and ease of use. With a commitment to reducing the daily burden of diabetes management, we create cutting-edge technologies designed to enhance the lives of those we serve. Join us in our journey towards a future where managing diabetes is simpler, more effective, and empowering.

Generics

Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. Additionally, CRV431 shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. The multiple mechanisms of action of CRV431 equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease. CRV431 has been tested in Phase 1 human clinical trials. Our drug candidate demonstrated good safety and tolerability in oral doses ranging from 75 mg to 525 mg. As expected, the pharmacokinetics of CRV431 showed increasing maximal blood concentrations as doses increased. Systemic blood exposures demonstrated good linearity up to 375 mg, which we anticipate will be more than sufficient for efficacy, based on our preclinical testing. The half-life of CRV431 was long and supports once daily oral administration. Data from our preclinical program and our phase 1 clinical trial support the further advancement of CRV431 in liver disease.

Honeywell is a Fortune 500 company that invents and manufactures technologies to address tough challenges linked to global macrotrends such as safety, security, and energy. With approximately 110,000 employees worldwide, including more than 19,000 engineers and scientists, we have an unrelenting focus on quality, delivery, value, and technology in everything we make and do. For additional information on how Honeywell processes your personal information please visit https://www.honeywell.com/privacy-statement.

Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

Biotech company specializing in drug discovery for hematologic diseases

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM. The Optimizer Smart is the first implantable device for the treatment of chronic heart failure in patients with normal QRS durations.

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

Ingenio Diagnostics (ID), a Genesis Drug Discovery and Development (GD3) Member Company, combines experience in Pharmaceutical, Biotechnology, and CRO services with a clinical diagnostic laboratory's licensure and accreditation. We deliver clinical diagnostic laboratory services and specialty testing with the additional benefit of dedicated quality assurance & quality control division. Our highly-skilled team of scientists, clinical, and operations personnel have extensive experience analyzing a wide variety of patient specimen types, spanning multiple analytical platforms in many therapeutic areas.

Generic and innovative specialty pharmaceutical products in injectable, ophthalmic dosage forms

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Integrated Analytical Solutions, Inc. (IAS), a Genesis Drug Discovery and Development (GD3) Company, is a contract research organization that provides analytical, bioanalytical and drug metabolism services to the pharmaceutical industry. The company was founded in 2004 to fill an unmet need for expert, economical and timely analytical services. Our laboratory is a state-of-the-art facility located in Berkeley, California within one of the world's most active life science research clusters (San Francisco Bay Area). The company is comprised of two operating divisions: GxP and Research and Discovery (R&D). The separate divisions enable the company to accommodate a wide range of projects and deliver fit-for-purpose methods based on each client's specific stage of development and budget. IAS offers each and every client boutique-level attention while providing cost-effective and timely data. Our track record for outstanding service and our collaborative spirit have resulted in long-lasting relationships with biopharmaceutical groups and academic laboratories around the globe.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

For over 30 years, Interchem has been successfully locating sources of fine chemicals, intermediates, bulk actives, and sophisticated next generation compounds from all over the world. With global capabilities, we are able to bring together materials and producers to supply almost any product. Through combining the expansive range of chemistries at our disposal with our in-house technical and regulatory expertise, we are able to successfully handle your diverse requirements in a quick and reliable manner. In addition, our project management and tracking systems ensure high levels of customer service at all times. Interchem prides itself on supplying a service that leverages professional sourcing with contracting expertise, technical assistance, and regulatory support.

Interpace Biosciences develops molecular diagnostic tests under the brand Interpace Diagnostics, and provides clincal trial services under the brand Interpace PharaSolutions.

WHO WE ARE iQure Pharma is uniquely positioned in developing new therapeutics solutions by bridging inventions stemming mostly from academia research with pharma industry, founded by entrepreneurs with strong pharmaceutical and financial industry background. OUR CORE COMPETENCIES Scouting for innovative compounds coming out of research from unmined academic sources. Evaluating out-licensing opportunities with big pharma and biotech for medical and commercial attractive targets. Selecting from that pool those compounds with a significant attractive target profile, which can support a future commercialization process. Driving and leading preclinical and clinical development activities, ensuring regulatory and quality compliance in all development tasks, while never losing focus on the final beneficiaries’ needs: the patients. Securing the required investment activities by assisting our investors in placing their funding in the most commercially viable therapies with attractive market potential and addressing clearly defined clinical needs.

iVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative therapies for clear vision and healthier eyes.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

Jeiven Pharmaceutical Consulting, Inc. (JPC) brings over twenty years of experience to our goal of providing pharmaceutical, biotechnology, medical device and dietary supplement companies with an unparalleled level of service and dedication to ensure the success of their projects. Our clients, which range from the small start-up to the large pharmaceutcial firms, come back to us because they know we will provide them with the highest level of service in combination with the expertise of our skilled consultants. The hallmark of our success has been our outstanding customer satisfaction and client retention. We take pride in providing, above all else, Reliable Guidance to clients of all sizes. Our areas of expertise include: 1) Clinical Trial Materials Project Management 2) Quality Assurance and Compliance 3) Auditing (contractors, suppliers, due diligence audits, mock-PAI audits, general GMP, GLP, GCP audits) 4) Training (GMP, GLP, GCP, DEA) 5) Regulatory Submissions (IND, IDE, CMC, 510(k), PMA, NDA, ANDA, eCTD) 6) Authoring SOPs and Quality Manuals 7)Formulation Development 8) Scale-up, Optimization and Method Transfer 9) Equipment Qualification 10) Analytical Method Development 11) Combination Drug / Device Products 12) Due Diligence Services for Venture Capital Firms 13) Process / Facilities Validation 14) Staffing 15) Comparator Drug Sourcing 16) Organizing the Clinical Supplies Support Group (CSSG) 17) Medical Device and In-vitro Diagnostics

JOGO Health uses wearable sensors and AI to treat chronic pain, migraine, post-stroke, and pelvic floor disorders using the foundational science of digital therapeutics.

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

J-STAR Research, Inc. is a contract chemistry organization serving as an outsourcing partner for the pharmaceutical and biotechnology industries. J-STAR is a leading provider of services in organic synthesis problem solving, early phase non-GMP and GMP manufacturing and crystallization R&D. While high quality synthetic chemistry and process research services continue to be J-Star’s foundation, the company has steadily added and continues to expand in the areas of QC, GMP and QA, Crystallization R&D, Solid Form and Polymorph Screening, Catalysis Screening + Enabling Technology, Highly Potent Compound Handling (HPAPI), Impurity Isolation and Structural Elucidation by NMR and HR-LC/MS and Preformulation for Drug Product Development. J-Star’s expert team of scientists and professionals coupled with solid industrial experience, a track record of dependability, and over 70,000 SF of well-equipped laboratories across two New Jersey research facilities ensures that all projects are delivered in full, on time and with rigorous quality.

Kamat Phamatech LLC is a privately held technology-based pharmaceutical company located in Central New Jersey. We specialize in the development, manufacturing, and approval of novel parenteral and enteral products and processes, particularly in the areas of new chemical and biological entities for treatments of various indications.

Developed a highly multiplexed imaging technology for microbial detection, providing unparalleled speed, breadth, and flexibility.

Kashiv BioSciences manufactures drug delivery systems and specialty drug products for the treatment of debilitating diseases.

Koios DS™ is a Smart Ultrasound™ solution for radiologists diagnosing cancer. Using AI algorithms trained on tens of thousands of images combined with data from pathology results, Koios DS™ is clinical decision support for a new era of diagnostic excellence. Smart Ultrasound™ redefines what radiology professionals can discern in the radiology suite. Our proprietary technology and patented methods provide an invaluable “second opinion” that is already being adopted by leading healthcare institutions to improve diagnostic accuracy, speed clinical decision making, and elevate the quality of care. Our software is FDA cleared for use in the USA. Koios DS. We put the AI in ultrasound.

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.

Headquartered in Somerset, NJ with offices around the world, LabVantage Solutions, Inc. provides laboratories with a comprehensive portfolio of informatics products and services, including LIMS (Laboratory Information Management System), integrated electronic laboratory notebook (ELN) and business intelligence. Our industry-leading solutions and services are the result of 35+ years of experience in laboratory informatics. We leverage that knowledge with state-of-the-art technology to help organizations redefine and optimize the way their laboratories conduct business. LabVantage has a solid track record of delivering return on investment to laboratories of all sizes. Our capabilities extend to legacy system migration, global laboratory harmonization, and laboratory business intelligence derived from disparate sites and systems. LabVantage delivers the best technical and domain expertise available to help you drive the success of your business. To find out more, visit us at: http://www.labvantage.com.

Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including SARS-CoV-2. Lactiga has earned awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.

Leading Pharma, LLC is a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. Our products are available in various dosage forms across many therapeutic areas under the Leading label. Product and Customer Related Inquiries – MEDICAL INFORMATION · Report Adverse Events / Side Effects · Report Product Complaints · Submit Medical Inquiries · Report Product Overdose and Poisoning Please contact us in the given details. By Phone: (844)-740-7500 By Fax: (973)-276-9656 By Email: micc_leadingpharma@mitoconbiopharma.com

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Genomic Prediction provides advanced genomic tests which improve IVF health outcomes. Genomic Prediction Inc. (GP) was incorporated in Delaware, May 1, 2017. The research insights which led to the creation of GP stretch back much further. Research and data exchange agreements to develop molecular methodology, signed with some of the largest biotechnology vendors in the world, were ongoing as early as 2015. In the decade prior, the founders’ work in embryology, detection of chromosomal abnormality, computational genomics, algorithms, and polygenic architecture led to GP’s superior and innovative methodology for the genetic testing of human embryos. GP’s products incorporate fundamental improvements on existing methods. GP offers IVF parents a cost-effective means to evaluate genetic risk due to chromosomal abnormality (ploidy), single-gene mutations, and polygenic diseases. Accurate understanding of the genomic architecture of human disease requires larger training datasets, greater accuracy, and a more rigorous, empirical basis of computational modeling (machine learning) than implemented in the past with simpler technologies and simpler computational methods. GP represents the next step in embryo genetic testing, combining dense, genome-wide genotyping methods with sophisticated validation-focused modeling, suitable for the information age.

Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. Linnaeus Therapeutics has been granted Orphan Drug Designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

LipoSeuticals is a specialty pharmaceutical company that engages in the development, manufacturing and commercialization of parenteral drug products.

(Formally Caladrius Biosciences; NASDAQ: CLBS) Lisata Inc., (LSTA) a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.

Medical Diagnostic Laboratories, L.L.C. (MDL), founded in 1997, serves primarily as a reference laboratory for Polymerase Chain Reaction (PCR) based testing to physicians, laboratories and hospitals worldwide. MDL is a CLIA certified infectious disease laboratory with multiple state licenses specializing in PCR technology. Molecular diagnostic techniques, such as the PCR method, are considered to be the most sensitive and specific for the laboratory diagnosis of infectious diseases. MDL offers unique, non-invasive, highly stable specimen collection and transport platforms, such as the OneSwab®, UroSwab® and NasoSwab®. These platforms enable MDL to offer a variety of PCR based tests from a single swab with high sensitivity and specificity. MDL specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties valuable tailored diagnostic information to assist in the detection, diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections. For example, the unique testing MDL offers for the specialties of Urology and Gynecology enables the detection of multiple pathogens as well as certain drug resistance profiles from a single swab by PCR. MDL's primary focus is in the field of infectious disease testing for Urology, Obstetrics and Gynecology, Respiratory Infectious diseases, Vector-borne diseases, Mycology and Pharmacogenomics. MDL is comprised of experts in the fields of Molecular Biology, Immunology, Virology, Microbiology, Mycology, Pharmacogenomics, Antimicrobial Resistance and Oncology. In addition to developing and validating new clinical diagnostic tests, the Research and Development Department also publishes research projects in peer-reviewed journals, presents scientific information at international symposia, and performs contractual research work for major commercial, governmental, and academic organizations.

MakroCare is expert Regulatory Consulting and Clinical Services partner for pharmaceutical, biotechnology and medical device industries. Our global/regional teams and fit-for-purpose costing models to your development strategy, regulatory management, clinical research, medical/scientific support and quality assurance areas. MakroCare has operations and presence in US, UK, EU, and Asia.

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.

MedChemExpress LLC, or MedChemExpress (MCE), is a biotech company based in New Jersey, USA, with locations in Princeton and Monmouth Junction. The company specializes in supplying high-quality research chemicals and biochemicals, including a vast selection of bioactive molecules such as selective inhibitors and recombinant proteins. These products are essential for pharmaceutical and life sciences research. MCE offers a variety of services to support research and development in the life sciences sector. Their services include custom synthesis for various compounds, protein expression and purification, and a comprehensive compound screening platform. They also provide molecular biology tools and cell biology services, which encompass cell culture and analysis. With a catalog of over 50,000 products, MedChemExpress is recognized for its contributions to drug discovery and research, serving a diverse global customer base in academia and industry.

Menssana Research is the leading developer of advanced new breath tests for detection of disease. We are now performing clinical studies with the BCA and with BreathLink (TM), mostly funded by the National Institutes of Health and BARDA, to evaluate breath testing in several diseases including lung cancer, breast cancer, heart transplant rejection, radiation exposure, and tuberculosis. The Food and Drug Administration has approved the Heartsbreath test for heart transplant rejection for clinical use. For more information, please visit menssanaresearch.com.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Mestastop Solutions is a biotechnology startup based in India, focused on addressing cancer metastasis. The company aims to develop innovative solutions to combat the spread of tumors, which significantly contributes to cancer-related deaths worldwide. Mestastop has gained global recognition for its research, presenting its work at major international conferences such as the American Association of Cancer Research Annual Conference and the European Association of Cancer Research. The company is involved in diagnostics and discovery related to cancer metastasis, with a focus on small molecule drugs to tackle distant metastasis. Mestastop's approach includes unraveling the biology of metastasis to create targeted treatments. The company has been vetted by the scientific outsourcing platform Science Exchange and is recognized as an authorized service provider, underscoring its credibility in the field.

MetasTx is creating treatments that prevent and treat prostate cancer metastasis without affecting the Androgen System. An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%. This area of research is ripe for advances. Unfortunately, current drug discovery in metastatic cancer has not resulted in therapies with significant increases in patient survival, specificity in drug delivery, or mitigation of deleterious side effects. MetasTx successfully concluded studies revealing the integral role of PAK1 in the regulation of epithelial-to-mesenchymal transition (EMT), a process necessary for early cancer cells to switch to metastatic ones. The stability and efficacy of MTX-101 are significantly superior in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer and demonstrate broad applicability across solid tumor cancers.

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Modern Meadow is focused on creating innovative biomaterials that make a positive impact on the world. Its main product, BIO-VERA®, is a transformative new sustainable material that is not only beautiful, but stronger and lighter than traditional materials. Made with over 80% renewable carbon content, BIO-VERA is crafted using BIO-ALLOY®, a flexible mix of proteins and polymers. This approach allows Modern Meadow to reduce reliance on oil-based and animal products without sacrificing quality. BIO-VERA is designed to easily integrate into existing production processes used by industries such as automotive, footwear, furniture and fashion accessories, making it a practical option for immediate use. Modern Meadow works closely with top brands like Tory Burch and industry leaders like BASF, Bader and ISA TanTec to ensure its products are of the highest quality and fully traceable from its lab to the brands people love. For more information, visit modernmeadow.com or follow the company on LinkedIn and Instagram. We are always open to connecting with strong talent and invite interested individuals to learn more by visiting the careers page of our website.

Montclair State University is a higher education institution that provides academic programs and services to students.

Electrodiagnostics

NeuroDx is a medical technology company that specializes in using non-invasive thermal dilution to detect fluid flow in CSF shunts.

Neurotez Inc. is a biotechnology company focused on developing a Leptin product as a hormone replacement therapy for Alzheimer's disease. Their mission is to become world leaders in biotechnology, utilizing an integrated platform from discovery to proof of concept clinical trials for CNS drugs.

Founded in 1895, Nexira is a family owned company who built its reputation as the world leader in acacia gum. Today Nexira is a global leader in natural ingredients and botanical extracts for food, nutrition, and dietary supplements. Our ingredients are perfectly suitable for the formulation of clean label products. Nexira manufactures in France a wide range of natural ingredients with recognized health benefits, such as Fibregum™ an all-natural, organic and GMO-free source of soluble dietary fiber. Nexira's portfolio for food industry includes a large range of branded natural acacia gum ingredients with exceptional functional properties (Emulsifiers & stabilizers, coating agents, texturizers, encapsulating agents…). Nexira's portfolio for supplement industry includes premium nutraceuticals, strongly supported with scientific & marketing supports, for digestive health, weight management, sports nutrition, joint health and men & women’s health.

Notitia ("NO-TEE-SHA") means "data" in Latin. We are a microbiome company that applies a data-driven approach to develop innovative products for the ecological restoration of a healthy gut microbiome.  Our mission is to promote health by protecting and/or restoring the Foundation Guild™ of the gut microbiome. Our vision is to maximize everyone's healthspan by keeping their gut microbiome to the healthiest possible status for the longest possible time. The work of Dr. Liping Zhao, co-founder of Notitia, shows that a healthy gut microbiome is dominated by a specific group of beneficial bacteria named the "Foundation Guild." The Foundation Guild™ not only produces beneficial compounds essential to human health but also creates an environment that can suppress the overgrowing pathogens. Restoration and maintenance of the Foundation Guild™ are fundamental to improve health and wellness in patients with unmet medical needs and the generally healthy population. Notitia has developed a revolutionary Foundation Guild™ R&D platform which consists of three technologies: identification, isolation & preservation, and nutritional formulas to support the Foundation Guild™ bacteria. Notitia has created several products based on the Foundation Guild™ R&D platform for patients as well as for the generally healthy population. Foundation Guild™ Wellness Program: a monthly subscription service that provides: 1. Guild:Plus microbiome nutrition 2. Guild:Health data tracking portal 3. Guild:Quest microbiome test kit 4. Guild:Save bio-banking 5. Guild:Pro personalized family-based probiotics. Foundation Guild™ Clinical Program: 1. NBT-NM108, a botanical drug for promoting the Foundation Guild, currently available in a phase 2 trial for COVID-19 and expanded access programs. Additional trials for MS, DKD, Cancer, and Parkinson's will be available by Dec 2021. 2. NBT-BM306, a live biotherapeutic product for restoring the Foundation Guild. Phase 1 trial will be available by Dec 2021.

NovaRock Biotherapeutics is an innovative and dynamic biotech company focusing on the development of antibody therapies for cancer and autoimmune diseases. NovaRock was founded in January 2018 in Princeton, New Jersey by a team of veteran scientists with proven track records in the advancement of biologics from discovery to commercialization.

Novelstar Pharmaceuticals Inc., founded in August, 2018, is a Company of Fosun Pharma focusing on the development of special pharmaceutical products of NDA and ANDA with advanced drug delivery systems. Our parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is a leading health and medical industry group in China. Fosun Pharma has a mission to promote human health. Its business covers the whole pharmaceutical industry chain, including drug manufacturing and R & D, medical services, medical device and medical diagnostics, pharmaceutical distribution and retail. Fosun Pharma has a state-of-the-art innovative technology center and an international R & D team. It continuously focuses on innovative research and development in cardiovascular, central nervous system, blood system, metabolism and digestive system, anti-infective and anti-tumor therapeutic fields. Facing the future, Fosun Pharma will adhere to the brand philosophy of "continuing to innovate and enjoy health" and continue to adhere to the development strategy of "endogenous growth, outward expansion and integrated development", and strive to become the first-class enterprise in the global mainstream medical and health market. Learn more on the FosunPharma website: https://www.fosunpharma.com/en/

NovoPedics, Inc. is developing implantable medical devices designed to relieve pain and restore mobility to patients suffering from severe meniscal injuries and meniscectomies. MeniscoFix™ is a polymer fiber-reinforced scaffold for total meniscus replacement designed to be gradually resorbed by the body and be replaced by new tissue. It represents an innovative approach to replace damaged meniscal tissue with a patented fiber-reinforced design similar to the native meniscus. It is designed to be attached to both soft tissue and bone, thus potentially enabling its use in total meniscus replacement surgery.

Nth Analytics pharmaceuticals consultants: CDISC SDTM/ADaM, biostatistics, and SAS programming.

Nuvectis Pharma is a biopharmaceutical company that focuses on developing novel targeted therapeutics for cancer treatment, including the oral small molecule inhibitor NXP800 targeting the Heat Shock Factor 1 pathway.

Odin Pharmaceuticals LLC is a sterile pharmaceutical company that develops injectable and ophthalmic drugs for the US marketplace.

Onkos Surgical is a privately held, specialty medtech company founded in 2015 that uses a digital platform and patient imaging analysis, to reconstruct bones following cancer therapy using personalized surgical planning and 3D printing.

Optimeos Life Sciences is pioneering a novel targeted gene delivery approach to advance medical treatment and patient care.

A life sciences company modernizing the way medicines are taken. Our mission is to improve patient outcomes through our next generation therapeutic delivery system, the Rapid Infusion Technology (RITe™) Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. With our proprietary manufacturing processes and state of the art cGMP-compliant facility in the U.S., we have developed our first product candidate, ORAVEXX™, a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and provide a safe, alternative treatment option to opioids. We are empowering the medical community by partnering with leading research institutions and physicians to support multiple FDA-authorized investigator-initiated clinical trials that utilize the RITe™ Platform to determine the safety and efficacy of CBD for the management of pain and inflammation.

Organon is a global healthcare company with a portfolio of therapies and products in women’s health, biosimilars, and established medicines across a wide array of conditions and diseases. Our mission is to deliver impactful medicines and solutions for a healthier every day. This site is intended for residents of the United States and its territories. You are reminded to protect yourself against recruiting fraud from individuals, organizations or other entities claiming to represent Organon. All official Organon recruitment emails will come from accounts formatted as name@organon.com or organon@workday.com, and Organon will never conduct interviews by chat or email, or make job offers through social media or online forums. All candidates for roles at Organon will first meet with a recruiter and interview team, via Teams or in person. Organon will never ask you to make financial transactions on its behalf or ask you to receive or ship packages or goods. For more information on adverse event reporting, visit http://bit.ly/AEReporting. To read our community guidelines, visit http://bit.ly/OrganonCommunityGuidelines. Follow us on Twitter at Organon (@OrganonLLC). Follow us on Instagram at Organon (@OrganonLLC).

Commercial stage medical device company, bringing together an elegantly simple evolution to robotic suture delivery and removal, with the best people in the medical device industry.

Orthobond is an antimicrobial technology company that has developed proprietary antimicrobial nanosurfaces, with broad applications in the medical device industry and more such as commercial, industrial, automotive, and beyond. We’re the first company to utilize nanoscale surface modifications that can be permanently bound to any surface, killing bacteria, viruses, and fungi by mechanically rupturing pathogens without using antibiotics.

Ortho Clinical Diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testingVitros Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrators - EUA 4/2020

Ortho Dermatologics is one of the largest prescription dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and corticosteroid-responsive dermatoses products. See our community guidelines at https://www.bauschhealth.com/social-media/.

With over 29+ years of global R&D and commercial experience in leadership roles managing teams and hands on pharmaceutical formulation development and commercialization, OSD Pharmaceutical Solutions LLC (an independent consulting firm) provides formulation and process development services to pharmaceutical companies. OSD PHARMA SOLUTIONS assists clients with development and selection, as well as overseeing of CDMOs for modified release coating/matrix systems, solubility enhancement, spray drying (SD), hot melt extrusion (HME), lipid-based formulations (softgels and liquid-filled capsules), tablets, chewable, OTD, Pediatric and taste-masking from development through registration, PV and commercialization. Expert in product development and commercialization (CMC, IND through NDA/ANDA) within the pharmaceutical industries with extensive understanding of global regulatory requirements (FDA, EMEA, USP, EP and JP) Therapeutic indications including: Oncology, UC, Parkinson, Alzheimer, HPV, HIV, CF and multiple rare diseases.

There are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.

Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system. The melanocortin system is involved in regulating important physiological activities such as food intake and energy balance, desire and arousal, and the resolution of harmful inflammation. We are the first company to obtain FDA approval for a melanocortin based therapeutic, Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD). With the successful development of Vyleesi® and our extensive experience in the development of melanocortin based therapeutics, we are now focused on developing therapeutics that take advantage of the key role that the melanocortin system plays in the resolution of harmful inflammation. This has the potential to treat diseases that affect the eye, gastrointestinal system and the kidney. Our most advanced ocular product is PL9643, a topical treatment for dry eye disease, which is targeted to enter Phase 3 clinical trials in 2H 2021. We also have therapeutics in earlier stages of development for ophthalmic indications such as non-infectious uveitis, retinopathies and corneal diseases. Therapeutics that modulate the activity of the melanocortin system will have broad utility and to establish this, we are planning to conduct proof of concept clinical studies in ulcerative colitis and kidney disease. Vyleesi® is the first and only on-demand, FDA-approved treatment for premenopausal women suffering with HSDD, which affects 1 in 10 pre-menopausal women. Learn about this condition here: https://www.unblush.com/ To learn more about Vyleesi®, including Important Safety Information, visit here: https://www.vyleesi.com/ We are very excited by the tremendous potential our therapeutics have to positively impact the lives of patients and the value we can build for our shareholders. Find more information about our programs: www.palatin.com

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.

Personal Cell Sciences is a Life Sciences company that specializes in developing and distributing personalized Adipose Derived Stem Cell based anti-aging, topical skin care products using individual's own stem cells.

At Petros, we are bringing new approaches to the most challenging conditions in men's health. We seek to understand the various health phases throughout a man’s journey. We collaborate with researchers, scientists, medical thought leaders and payers to ensure our therapies aid in restoring men’s body function to vitality. Please see the full Prescribing Information and Patient Information: https://stendra.com/wp-content/uploads/2022/04/stendra-prescribing-information.pdf https://stendra.com/wp-content/uploads/2022/04/stendra-patient-information.pdf

PhageNova Bio is a company that has developed a targeted gene delivery vector. The company is engaged in pioneering targeted gene expression for gene therapy.

We are drug development experts that use a simple and cost-effective business model to provide targeted expertise and broad development experience to help you move forward while managing risk, cost and time.

PharmaNest is an image analysis and contract research company focused in the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

Porton Advanced is a Cell and Gene Therapy (CGT) CDMO/CRO. We provide end-to-end research grade, process development (PD), analytical development (AD), GMP manufacturing, and testing services of AAV, Lentivirus, mRNA, and plasmid to meet clients’ therapeutic product needs at pre-clinical, clinical, and commercial stages. Our dedicated process and analytical development teams have established robust platform-based USP/DSP and GMP manufacturing capability and capacity, as well as proprietary technologies to further empower our clients’ successes. Our services include gene and cell engineering discovery research and technology licensing, process development and analytical development, testing, drug substances (DS) and drug products (DP), and cGMP manufacturing across plasmids, cell therapy, gene therapy, virotherapy, and mRNA-based therapeutic platforms.

PeproTech was established in 1988 by a group of scientists who decided to focus their efforts on the development and production of recombinant cytokines for life-science research. Today, we are a business unit within the Thermo Fisher Scientific BioSciences Division. Our team is dedicated to advancing solutions that enable our customers to accelerate research and discovery to solve the world’s most complex scientific challenges. PeproTech specializes in manufacturing and supplying high quality cytokine products and exceptional service to the life science and cell therapy markets around the world. Our products are distributed worldwide through customer-service offices in the US, UK, France, Germany, Israel, Korea, China and Japan. A key component in keeping up with current scientific advancements has been our collaboration with researchers in both academia and industry. We encourage you to convey to us your particular research needs and promise to do our best to fulfil them. Part of Thermo Fisher Scientific, the world leader in serving science.

We bring an aggregate 80+ years of diverse experience in solving complex issues with preclinical drug candidates by identifying creative and innovative solutions for key problems with drug delivery, exposure, chemical and physical stability, drug metabolism, safety, and toxicity. IP expert witness.

Princeton BioMeditech Corporation develops rapid, point-of-care diagnostics. Utilizing its patented technologies, PBM has developed and introduced an extensive menu of over 70 different one-step/rapid tests.COVID-19: EUA (02/2021)

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The company's lead product, SANGUINATE™, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________

PSG Life Sciences is a management consulting firm advising companies on issues of sales, marketing and business development strategy, operations and tactical execution. We work with domestic and international companies selling into the Biomedical, R&D and Clinical Diagnostic markets (Academic, Global Pharmaceutical, Biotech and Government, etc.). PSG Life Sciences has helped companies, their salespeople, and executive teams develop strategy, process, and skills to improve sales productivity and top-line growth. Unlike alternatives, we offer a unique performance based consulting model that guarantees results.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Welcome to Regenicin specializing development regenerative cell therapies, NovaDerm®

Collagen Matrix is now Regenity Biosciences. Regenity Biosciences advances new frontiers in regenerative science, turning bioabsorbable materials into life-changing solutions. Sought after for our novel resorbable technologies and distinct approach to contract manufacturing and contract development, our team brings the urgency and vision to deliver breakthrough medtech solutions for medical technology and medical device manufacturers of all sizes. Company Background For more than 25 years, Regenity Biosciences has been transforming bioabsorbable materials into regenerative solutions to repair and regenerate tissue and bone we have since introduced numerous bioresorbable technologies with more than 71 product lines commercially available worldwide. Most recently, Regenity expanded its product portfolio to include versatile bioresorbable polymer technologies via the acquisition of Polyganics, which was the impetus behind the new name and brand direction. Regenity is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Mission & Values Every day, we work to make a material difference in the lives of patients. With people’s health on the line, it’s our duty to act with urgency and diligence. It is this collective ethos that drives us each day to push the boundaries of what’s possible in tissue repair and regeneration. Looking for a Career with Purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our website to learn more about what sets Regenity apart. www.Regenity.com CMIContact@CollagenMatrix.com

ReGenTree, LLC is a newly created U.S. joint venture company owned by HLB Therapeutics (formerly GtreeBNT Co., Ltd.), a bio venture company in Korea. The company was founded with the aim of becoming a global leader in the pharmaceutical industry for ophthalmic disorders.

Our (re)Vision: Bring impactful ophthalmic medicines to as many patients as possible as quickly as possible. The company is pursuing products that address unmet needs, can be priced for access, and still have substantial commercial potential. reVision Therapeutics, Inc. was founded in 2018 to develop medicines with high disease impact, and rapidly get those medicines to patients. The company prioritizes areas of unmet or poorly met needs in ophthalmic disorders by repurposing approved or rescuing shelved drugs that could change patients’ lives. Repurposing or rescuing drugs allows for faster development at a reduced cost. Our lead program is a product for Stargardt disease, a retinal degenerative disease that often begins in childhood. Our candidate is a repurposed, GRAS (generally recognized as safe) cyclodextrin delivered intravitreally that could work as a first-line therapy or in combination with other products currently in development. It can be developed fast and produced at a relatively low cost. Other targets include a repurposed drug for dry eye disease, a rescued therapy for proliferative vitreoretinopathy, and a combination product to treat intraocular pressure.

In 2017, IEH Laboratories and Consulting Group acquired the Atlas technology from Roka Bioscience. The IEH Laboratories and Consulting Group family of companies continues to grow. IEH now employs more than 1,800 employees in eight countries (Australia, Austria, Canada, China, England, Germany, Mexico, and the USA). We also recently completed the acquisitions of: Sample6, Unitech, Toximet, Biomerx Laboratorium GmbH, VIL Institut fur Lebensmittelsicherheit, Labor Iben GmbH, and Iben Mikro Stop GmbH. In addition, we have expanded our expertise by welcoming new experts to the IEH family for consulting services including former FDA, USDA and industry senior leaders to further assist the food industry. The Roka and Sample6 acquisitions have allowed us to expand our capabilities in rapid pathogen detection and automation. We have now validated both systems for the detection of Listeria in food samples after only 10-15 hours of enrichment, and same day results are available for environmental samples

Rutgers University is an academic institution that offers a wide range of undergraduate and graduate programs, conducts research, and provides educational services.

RVL Pharmaceuticals (previously named Osmotica Pharmaceutical; Nasdaq: OSMT) is a fully-integrated pharmaceutical company with demonstrated expertise in developing commercially successful products. As one of the world's leading osmotic drug delivery companies, we leverage our significant resources in R&D and proprietary drug delivery technology to address the growing need of the global patient population. We have the resources and experience to successfully commercialize our products through our subsidiaries, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC.

Salvona Technologies LLC is focused on manufacturing proprietary advanced encapsulation systems that modify the way functional and active ingredients are being delivered. These systems are used to formulate innovative and highly functional products with unique features, including long-lasting release, triggered release, and targeted delivery. The encapsulation technologies are designed to address production and application issues, such as stability of raw materials, formulation practicality, environmental and safety concerns, and user compliance. Salvona has established an umbrella of intellectual property covering its broad technology platforms that provides the company with the freedom to operate and apply these technologies in various markets including consumer health care, dermatology, pharmaceuticals, cosmetics, oral hygiene, and general consumer care. Salvona’s patent portfolio covers both the compositions and applications of its technology platforms. Since its founding, the company has applied for nearly 100 patents. Salvona is privately owned and operates in partnership with ZSCHIMMER & SCHWARZ CHEMIE GmbH.

Based on RUCDR Infinite Biologics, which was founded in 1999 to provide biobanking services and biomaterials to advance the genetic disease research of partners in the public and private sectors. Following the spinout, Infinity Biologix said it will provide sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas.COVID-19: COVID-19 Saliva test. In April 2020, IBX (formerly Rutgers RUCDR Infinite Biologics) received the first FDA Emergency Use Authorization (EUA) enabling the use of saliva tests to detect the presence of the SARS-CoV-2 coronavirus. Since then, a revised EUA for anat-home saliva sample collectionwas also approved.

Samsara Vision, Inc. is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans. Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services.

Sannova is a boutique CRO with a unique Z factor approach, prioritizing high standards and exceptional services for clients. We offer fast, personalized, end to end analytical and bioanalytical services for complex, novel, and generic therapeutics. Our core values of quality, speed, and flexibility enable us to deliver exceptional results via our passionate team of expert scientists. Our commitment to reliable and reproducible results gives clients confidence in their therapeutic development.

Sciecure Pharma, Inc. is a US based, specialty pharmaceutical company, driven by a highly dedicated team, with 10,000 sq-ft laboratory and office space in Monmouth Junction, New Jersey. The current focus of the company is on research and development of high barrier drug products.

SCIMEDX is a diagnostic manufacturer with over 30 years of proven experience. Best known for its range of autoimmune and infectious disease testing products. Scimedx extends it's platforms for disease testing. The first was ImmuoCyt+ an FDA cleared & patented assay for bladder cancer. From there Scimedx expanded it's IFA and Latex Infectious assays by acquiring PANBIO for HHV, Dengue, West Nile. Scimedx then went on to acquire Parasitology serology assays from IVD Research. Continuing it's growth, Scimedx has finalized it's rapid testing platform. Scimedx is the de-facto manufacturer of IFA, ELISA, Agglutination tests, delivering solutions for disease testing worldwide.

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Sentrimed is a clinical stage biotechnology company developing novel targeted therapies that harness cell-to-cell communication pathways essential to reviving the body's ability to recognize, immobilize and eliminate tumor cells. Sentrimed is a leader in contact normalization, a cellular communication process that enables normal cells to inhibit tumor proliferation and migration, and trigger tumor cell destruction. Tumor cell motility and survival are core issues in cancer impacting proliferation, migration, metastasis and overall patient prognosis. When mutagenesis occurs and normal cells are transformed into tumor cells, podoplanin (PDPN) is induced, disrupting normal cell-to-cell communication, and allowing tumor cells to escape contact normalization, proliferate and migrate. PDPN, a transmembrane glycoprotein receptor that is an early expressed tumor biomarker, is overexpressed in many cancers and is correlated with poor outcomes. Our lead product, MASL®, is a novel, orally dosed, bioactive lectin. MASL potently inhibits PDPN and blocks PDPN mediated activation of Cdc42 and downstream signaling important to cancer progression. MASL revives contact normalization to inhibit tumor cell proliferation and migration, and triggers destruction. MASL has demonstrated both cytostatic and cytotoxic effects on drug resistant human oral squamous cell carcinoma (OSCC) cells. Animal studies have not produced any identifiable adverse effects. The first indication we will seek is Head and Neck Cancers (HNC) which is a rapidly growing market with significant unmet needs.

SHINKEI is a clinical stage CNS (Central Nervous System) disorders focused pharmaceutical company using the 505(b)2 regulatory strategy to repurpose existing pharmaceutical products for faster and better patient outcome. We have a diversified and robust product development pipeline focus on improving a drug's administration such that it allows use in indications not previously possible, enhances the convenience, improves compliance, and/or ameliorates the side-effects profile for patients SHINKEI was co-founded by Suresh Borsadia and GP Singh, industry veterans, having the mix of commercial and scientific backgrounds. They are supported by a nimble and efficient team of professionals, advisors and consultants.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances. Signum’s phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics. Signum has established a robust IP portfolio in the area of Signal Transduction Modulators (STMs). Signal transduction networks that regulate cellular activities have built-in global control mechanisms to coordinate their many interacting components. Signum has identified agents that perturb the two most central of these global regulatory mechanisms: G-Protein-Mediated membrane receptor signaling and Protein phosphorylation. G-Protein modulators (GPMs) regulate virtually all G-protein-mediated signaling activities and Phospho-Protein modulators (PPMs) regulate protein kinase phosphorylation networks. GPMs and PPMs can be used as cosmetics and dietary supplements to correct stressful imbalances that can be detrimental to health and well-being.

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders.

As a premier, independently owned CDMO with over 65 years of sterile injectable manufacturing experience, Simtra BioPharma Solutions offers world-class cGMP sterile fill/finish, technical expertise, quality service, and a uniquely collaborative approach. Pharmaceutical and biotech companies partner with us when they face formulation challenges, clinical supply hurdles, surges in demand due to market fluctuations, or risk mitigation concerns. Our teams are driven to offer our clients tailored and versatile solutions to help them bring their products to market so they can get to the patients who need them. (Simtra is a tradename of Baxter Oncology GmbH and Baxter Pharmaceutical LLC)

SkinAxis is a biotechnology company that provides multicellular skin equivalent systems that reproduce the physiological properties of human skin tissues. These models represent the response of human skin to drug and active ingredient treatment more accurately then animal models. SkinAxis multicellular three-dimensional tissues can be customized using cell types engineered to specifically express gene reporter systems. These advanced models allow the faster, more sensitive, and more accurate assessment of the preclinical activity profile of drugs and active compounds. All products by SkinAxis are made in Inited States of America We seek to provide and develop solutions for cosmetic, biotechnology, pharmaceutical, chemical and diagnostic companies and academic laboratories interested in active ingredient testing and drug discovery

Skunkworx Bio (SKWX) is a drug discovery powerhouse obsessed with building novel therapeutics for major unmet medical needs. SKWX expertise comes from two decades of molecular engineering experience with leaders in the field of biologic intervention. The company’s unique and proprietary technical platform allows for the generation of new biological entities unknown to biology and outside the human repertoire of possibilities.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.  Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®.  We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).

As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process.

SpotitEarly is revolutionizing cancer pre-screening with an innovative AI-based test that can detect multiple cancer types from a single breath sample. This simple solution allows for easy, at-home sample collection in minutes, without any healthcare professional assistance. Our off-the-shelf test is affordable and available everywhere, at everyone’s convenience, removing the barriers that keep about half of the people from getting tested on time. With an impressive 94% accuracy (sensitivity and specificity), our technology has been shown to be effective even in early-stage cancer detection, which can significantly increase treatment options and survival rates. By harnessing the science of scent, SpotitEarly identifies cancerous VOCs in exhaled breath. This smart technology enables more frequent testing of wider audiences at a fraction of the cost, ultimately saving lives and improving clinical outcomes globally. We envision a world where hassle-free pre-screening is the norm. Join us in our mission to make cancer prevention easy, effective, and universally accessible, bringing enhanced quality of life and peace of mind for all.

Starton Therapeutics is a clinical-stage biotechnology company that is transforming standard-of-care therapies with proprietary dermal technology, so people with cancer can receive continuous treatment to live better, longer. Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are the most common blood cancers in the United States. There is no treatment to help people with CLL to stay in remission, and while advances in treatment have provided people with MM a multitude of treatment options, they struggle with long-term tolerance of high doses, which may be more effective but come with a multitude of side effects. Starton's team of some of the best in clinical development and hematology/oncology have come together to change the fate for people struggling with the impact of their diseases. If dose-related side effects can be reduced and people can tolerate maintenance therapy for decades to help stay in remission, these cancers – which were previously a death sentence – would become more akin to chronic diseases, with a long lifespan and healthy quality of life. Starton is one of the few life sciences companies funded exclusively by individual investors. We have a business model that is lower risk, faster to market and less capital intensive than biotech companies developing medicines from scratch.

Stira Pharmaceuticals is a Sterile Injectable CDMO with deep pharmaceutical product development and manufacturing experience in small molecules and peptides. At Stira Pharmaceuticals, a team of highly skilled and experienced scientists are developing challenging products using in-house technology platforms, technical know-how and in-depth prior experience. We offer services: Analytical R &D Preformation In Vitro Permeability Testing (IVPT) In Vitro Release Testing (IVRT) Extractables & Leachable Testing (E & L) Formulation Development Stability Testing Microbiology Regulatory Support

Sunrise Pharma is a premier provider of safe and affordable generic medicines. Sunrise was founded and is based in the United States. Our products appear in various dosage forms across multiple therapeutic areas. We market products to all pharmaceutical channels including local and national retailers, wholesalers, distributors, health systems, and government. We understand the role of medicine in our society and we are wholly committed to supplying top notch quality products to the US pharmaceutical market. Our aim is to provide a diverse portfolio of safe and affordable generic medications to millions of patients to lead a happier and healthier life.

Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology work, including but not limited to, oligo synthesis, gene synthesis, subcloning & PCR cloning, plasmid preparation, mutagenesis, DNA variant libraries, CRISPR sgRNA, protein expression and purification in multiple systems. Relying on our strong DNA sequencing, synthesis, engineering technology platform, and expertise in bioinformatics analysis, we have developed proprietary algorithms to facilitate and expedite the antibody discovery process. Our antibody discovery services include hybridoma sequencing, immune repertoire sequencing, antibody design and production, AI-guided heavy chain and light chain pairing, antibody humanization, affinity maturation, and sdAb.

The Tabula Rasa HealthCare family of companies provide new beginnings for our clients, through innovative service models and fresh approaches to healthcare technology. Our leaders understand that to maximize patient experiences and outcomes, they must help providers to balance efficiency and scalability with safety and individualization of care.

Tara Innovations LLC is formulation contract research organization (CRO). We specialize in product development, technology management, analysis, and process development. We do preformulation and pharmaceutical consulting. We are expert in nanotechnology.

TAXIS Pharmaceuticals is a biotech company devoted to combatting the serious and deadly societal threat of antibiotic resistance by creating therapies that address the root cause of the issue. We're developing therapies that, when used in combination with FDA-approved antibiotics, are intended to restore the efficacy of those medications. We currently have one investigational therapy that has completed Ph1 human trials, and several additional products in the pipeline.

A new treatment for cancer

Teligent is a pharmaceutical company that develops, manufactures and markets topical medicines and sterile injectable products.

Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company’s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio’s foundational vision is a healthier world through equitable access to lifesaving innovations.

We are an independent, full-service, family-owned CRO specializing in dermatology since 1944. We manage global phase 2/3 trials in conjunction with our standalone phase I unit. Our structure and experience allow us to approach each and every study with agility and innovation, providing our sponsors with a truly bespoke turnkey solution. We are not your traditional CRO.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company’s lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company’s lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer’s disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients' needs in neuroscience and other therapeutic categories. Our science and technology make us unique, but it is our team members that set us apart; they are the engine that fuels Tris' passion and innovation. The Tris team comprises of approximately 500 diverse individuals; one third of whom operate in the field throughout the U.S. while the other two-thirds work from Tris' NJ operations. Tris colleagues understand the criticality of operating a successful business and take pride in the company's success. But of equal importance to each member of the team is how we interact with one another on a daily basis. We believe in each other and we believe in respectful, open and honest communications to help support individual and team success. At Tris we strive to ensure our field and home office teams are connected and engaged. We listen to our teams in numerous ways including through our Diversity & Inclusion Committee and our Women's Business Council to help to ensure every employee's voice is heard. After all, it is our daily interactions with one another that build and sustain our culture which fuels our growth.

University Hospital is a healthcare facility that provides medical services and health services.

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

We Specialize in Urology and Women’s Health Care.Pain, urgency, frequency. Every day, urologic disorders continue to affect the lives of people all around us. Vaneltix is focused on providing immediate relief for patients suffering from Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), a disease of the lower urinary tract that predominantly affects women.

Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery. Sirogen™ is currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes in patients requiring an arteriovenous fistula for hemodialysis.

Vivozon is a pharmaceutical drug development company.

Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our strategy is to develop products first for osteosarcoma, a rare bone cancer that largely effects adolescents, and then extend to other cancers. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de-risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs. In Comparative Oncology, canine patients with naturally occurring cancer are included in clinical trials for benefit of humans and human's best friend. Dog osteosarcoma is highly relevant to human osteosarcoma; drugs effective in the dog are highly relevant to the human. A further advantage of dogs that is crucial in cancer recurrence trials is the that fact that in dogs the cancer process is sped up, so that what happens over a time frame of a few years in humans is compressed into months in dogs.

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBET™ Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with significant unmet medical needs. BETs are a family of proteins that are believed to play a causal role in the regulation of inflammatory genes that are implicated in numerous diseases. VYNE has done the first formative work in applying BET inhibition to the treatment of autoimmune disease. The company’s leadership is demonstrated in clinical development, where VYNE is building a superior body of evidence that informs the advancement of its two lead product candidates: VYN201 for the treatment of vitiligo; and VYN202, a highly potent and selective BET inhibitor that offers promise across a broad array of chronic autoimmune indications. To learn more about us and our pipeline, visit vynetherapeutics.com. Read our Social Media Guidelines here: https://vynetherapeutics.com/social-media-guidelines/.

WCG is a true partner to research sponsors, CROs, sites and participants in navigating the clinical research journey. The pioneer of independent ethical review, now the industry gold standard, WCG's 55-year legacy of independent review solutions serves as the foundation on which we continually build to accelerate and improve the clinical research journey. We lead the way by reimagining processes, optimizing quality and safety, strengthening productivity, and pioneering new solutions that leverage data and technology to accelerate research and impact global health. WCG liberates study stakeholders from the constraints that risk trial efficacy while improving quality outcomes and efficiency through the process. Ninety percent of all clinical trials leverage our knowledge, highly specialized solutions, and data-driven insights to mitigate risk today for a more promising tomorrow.

Generic injectables

XEME Biopharma Inc. is clinical-stage company focused on developing therapeutic products in the area of active cancer immunotherapy (vaccines). This area of therapeutic cancer vaccines is expected by many oncology specialists to provide the next breakthrough in the treatment of cancer beyond the current approaches of surgery, radiation, chemotherapy and passive immunotherapy (monoclonal antibodies). XEME Biopharma is focused on two integrated technology platforms: Aggregon® and Oncolipin. The Aggregon® technology is used in the manufacture of Oncoquest™-CLL and Oncoquest™-L, two innovative lead products of personalized (autologous) cancer vaccines for the treatment of leukemia and lymphoma, respectively. XEME's unique, disruptive, and patented technology platform has the following competitive advantages: - Indicated efficacy in previous clinical studies - Very low cost of production / high margins - Broad spectrum of potential clinical applications - personalized and off-the-shelf products - Rapid manufacturing process, less than 24 hours - Relatively low cost per dose, per patient

YARAL Pharma Inc. is the US subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they're cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service.

Zena Therapeutics is a drug discovery company, spun-out of Rutgers University, designing new medications for mental health and addiction by improving safety profiles. Currently the work at Zena focuses on acute anxiolytic compounds that do not increase the risk of overdose if taken concomitantly with other central nervous system depressing substances such as opioids and alcohol.